Determining the optimal PD‐1/PD‐L1 inhibitors for the first‐line treatment of non‐small‐cell lung cancer with high‐level PD‐L1 expression in China

Determining the optimal PD‐1/PD‐L1 inhibitors for the first‐line treatment of non‐small‐cell lung cancer with high‐level PD‐L1 expression in China

Abstract Background and Objective The programmed death 1 and ligand (PD‐1/PD‐L1) inhibitors have significantly altered therapeutic perspectives on non‐small‐cell lung cancer (NSCLC). However, their efficacy and safety are unknown since direct clinical trials have not yet been performed on them. It i...

Full description

Bibliographic Details
Main Authors: Meng‐Meng Teng, Si‐Ying Chen, Bo Yang, Yan Wang, Rui‐Ying Han, Meng‐Na An, Ya‐lin Dong, Hai‐Sheng You
Format: Article
Language:English
Published: Wiley 2021-09-01
Series:Cancer Medicine
Subjects:
cost‐effectiveness
efficacy
non‐small lung cancer (NSCLC)
PD‐1/PD‐L1 inhibitors
safety
Online Access:https://doi.org/10.1002/cam4.4191

Internet

https://doi.org/10.1002/cam4.4191

Similar Items